*** CHEMICAL IDENTIFICATION ***

RTECS NUMBER            : MI9750000
CHEMICAL NAME           : Heptanedioic acid,
                          mono(2-(4-((2,6-dideoxy-2-fluoro-alpha-L-talopyranosy
                          l)oxy)-1,2,3,4,6,11-
                          hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-na
                          phthacenyl)-2-oxoethy l) ester, (2S-cis)-
CAS REGISTRY NUMBER     : 116521-53-0
LAST UPDATED            : 199403
DATA ITEMS CITED        : 3
MOLECULAR FORMULA       : C34-H37-F-O15
MOLECULAR WEIGHT        : 704.71
COMPOUND DESCRIPTOR     : Drug
SYNONYMS/TRADE NAMES :
   *   7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)adriamycinone-14-O-hemip
     imelate
   * 7-O-(2,6-Dideoxy-2-fluoro-alpha-L-talopyranosyl)pimelyladriamycinone
   * FAD-104
   * FT-Adm
   * ME2303
 
                       *** HEALTH HAZARD DATA ***
 
                        ** ACUTE TOXICITY DATA **
 
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 179 mg/kg
TOXIC EFFECTS :
   Nutritional and Gross Metabolic - weight loss or decreased weight gain
   Behavioral - muscle weakness
REFERENCE :
   DECRDP Drugs under Experimental and Clinical Research.  (Bioscience
   Ediprint, Blvd. James-Fazy 13, 1201 Geneva 1, Switzerland)  V.1-    1977-
   Volume(issue)/page/year: 14,435,1988
 
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 72800 ug/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   DRFUD4 Drugs of the Future.  (J.R. Prous, S.A., Apartado de Correos 540,
   08080 Barcelona, Spain) V.1-    1975/76-  Volume(issue)/page/year:
   14,756,1989
 
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 138 mg/kg
TOXIC EFFECTS :
   Nutritional and Gross Metabolic - weight loss or decreased weight gain
   Behavioral - muscle weakness
REFERENCE :
   DECRDP Drugs under Experimental and Clinical Research.  (Bioscience
   Ediprint, Blvd. James-Fazy 13, 1201 Geneva 1, Switzerland)  V.1-    1977-
   Volume(issue)/page/year: 14,435,1988
 
                            *** END OF RECORD ***